414 related articles for article (PubMed ID: 29256987)
1. APPLICATION OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY TO ASSESS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN MYOPIC CHOROIDAL NEOVASCULARIZATION.
Cheng Y; Li Y; Huang X; Qu Y
Retina; 2019 Apr; 39(4):712-718. PubMed ID: 29256987
[TBL] [Abstract][Full Text] [Related]
2. Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conventional fluorescein angiography.
Iacono P; Giorno P; Varano M; Parravano M
Eur J Ophthalmol; 2021 Jan; 31(1):149-157. PubMed ID: 31619075
[TBL] [Abstract][Full Text] [Related]
3. CORRESPONDENCE OF LEAKAGE ON FLUORESCEIN ANGIOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY PARAMETERS IN DIAGNOSIS AND MONITORING OF MYOPIC CHOROIDAL NEOVASCULARIZATION TREATED WITH BEVACIZUMAB.
Battaglia Parodi M; Iacono P; Bandello F
Retina; 2016 Jan; 36(1):104-9. PubMed ID: 26166803
[TBL] [Abstract][Full Text] [Related]
4. Spectral-Domain Optical Coherence Tomography of Subretinal Hyperreflective Exudation in Myopic Choroidal Neovascularization.
Bruyère E; Caillaux V; Cohen SY; Martiano D; Ores R; Puche N; Souied EH
Am J Ophthalmol; 2015 Oct; 160(4):749-58.e1. PubMed ID: 26164828
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
6. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization.
Parravano M; Ricci F; Oddone F; Missiroli F; De Felici C; Varano M
Retina; 2014 Oct; 34(10):2053-62. PubMed ID: 24946101
[TBL] [Abstract][Full Text] [Related]
7. Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization.
Howaidy A; Eldaly ZH
Eur J Ophthalmol; 2021 Jan; 31(1):211-217. PubMed ID: 31690105
[TBL] [Abstract][Full Text] [Related]
8. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
9. A new treatment algorithm for the management of myopic choroidal neovascularization using intravitreal ranibizumab.
Iacono P; Parodi MB; Papayannis A; La Spina C; Varano M; Bandello F
Acta Ophthalmol; 2015 Sep; 93(6):e519-20. PubMed ID: 25828793
[No Abstract] [Full Text] [Related]
10. Intravitreal Ranibizumab for myopic choroidal neovascularization after pars plana vitrectomy and silicone oil tamponade.
Cascavilla ML; Querques G; Querques L; Codenotti M; Bandello F
Eur J Ophthalmol; 2013; 23(6):913-6. PubMed ID: 23813105
[TBL] [Abstract][Full Text] [Related]
11. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
12. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
Lee JY; Chung H; Kim HC
Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
14. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.
Ruiz-Moreno JM; Montero JA; Amat-Peral P
Graefes Arch Clin Exp Ophthalmol; 2011 Apr; 249(4):595-9. PubMed ID: 21234588
[TBL] [Abstract][Full Text] [Related]
15. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
16. Fluorescein Leakage and Optical Coherence Tomography Features of Choroidal Neovascularization Secondary to Pathologic Myopia.
Battaglia Parodi M; Iacono P; Romano F; Bandello F
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3175-3180. PubMed ID: 30025121
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
18. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
[TBL] [Abstract][Full Text] [Related]
19. Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.
Romdhane K; Zola M; Matet A; Daruich A; Elalouf M; Behar-Cohen F; Mantel I
Br J Ophthalmol; 2020 Jul; 104(7):910-916. PubMed ID: 31615761
[TBL] [Abstract][Full Text] [Related]
20. Features of optical coherence tomography predictive of choroidal neovascularisation treatment response in pathological myopia in association with fluorescein angiography.
Lee DH; Kang HG; Lee SC; Kim M
Br J Ophthalmol; 2018 Feb; 102(2):238-242. PubMed ID: 28600301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
